Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2976-2983
Published online before print December 3, 2007, doi: 10.1161/CIRCULATIONAHA.107.707257
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
116/25/2976    most recent
CIRCULATIONAHA.107.707257v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, L.
Right arrow Articles by Chen, Y. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, L.
Right arrow Articles by Chen, Y. E.
Related Collections
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Heart failure - basic studies
Right arrow Hypertrophy
Right arrow Myocardial cardiomyopathy disease
Right arrow Type 2 diabetes

(Circulation. 2007;116:2976-2983.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

Rad GTPase Deficiency Leads to Cardiac Hypertrophy

Lin Chang, MD, PhD*; Jifeng Zhang, MS*; Yu-Hua Tseng, PhD; Chang-Qing Xie, MD, PhD; Jacob Ilany, MD; Jens C. Brüning, PhD; Zhongcui Sun, MD; Xiaojun Zhu, MD; Taixing Cui, MD, PhD; Keith A. Youker, PhD; Qinglin Yang, MD, PhD; Sharlene M. Day, MD; C. Ronald Kahn, MD; Y. Eugene Chen, MD, PhD

From the Cardiovascular Center (L.C., J.Z., C.-Q.X., T.C., S.M.D., Y.E.C.), Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich; Joslin Diabetes Center (Y.-H.T., J.I., J.C.B., C.R.K.), Harvard Medical School, Boston, Mass; Institute of Molecular Medicine (Z.S., X.Z.), Peking University, Beijing, People’s Republic of China; Department of Cardiology (K.A.Y.), The Methodist Hospital Research Institute, Houston, Tex; and Cardiovascular Research Institute (Q.Y.), Morehouse School of Medicine, Atlanta, Ga.

Correspondence to Jifeng Zhang or Dr Y. Eugene Chen, Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109. E-mail jifengz{at}umich.edu or echenum@umich.edu

Received April 2, 2007; accepted September 25, 2007.

Background— Rad (Ras associated with diabetes) GTPase is the prototypic member of a subfamily of Ras-related small G proteins. The aim of the present study was to define whether Rad plays an important role in mediating cardiac hypertrophy.

Methods and Results— We document for the first time that levels of Rad mRNA and protein were decreased significantly in human failing hearts (n=10) compared with normal hearts (n=3; P<0.01). Similarly, Rad expression was decreased significantly in cardiac hypertrophy induced by pressure overload and in cultured cardiomyocytes with hypertrophy induced by 10 µmol/L phenylephrine. Gain and loss of Rad function in cardiomyocytes significantly inhibited and increased phenylephrine-induced hypertrophy, respectively. In addition, activation of calcium-calmodulin–dependent kinase II (CaMKII), a strong inducer of cardiac hypertrophy, was significantly inhibited by Rad overexpression. Conversely, downregulation of CaMKII{delta} by RNA interference technology attenuated the phenylephrine-induced hypertrophic response in cardiomyocytes in which Rad was also knocked down. To further elucidate the potential role of Rad in vivo, we generated Rad-deficient mice and demonstrated that they were more susceptible to cardiac hypertrophy associated with increased CaMKII phosphorylation than wild-type littermate controls.

Conclusions— The present data document for the first time that Rad is a novel mediator that inhibits cardiac hypertrophy through the CaMKII pathway. The present study will have significant implications for understanding the mechanisms of cardiac hypertrophy and setting the basis for the development of new strategies for treatment of cardiac hypertrophy.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Circ. Res.Home page
M. Metrich, A. Lucas, M. Gastineau, J.-L. Samuel, C. Heymes, E. Morel, and F. Lezoualc'h
Epac Mediates {beta}-Adrenergic Receptor-Induced Cardiomyocyte Hypertrophy
Circ. Res., April 25, 2008; 102(8): 959 - 965.
[Abstract] [Full Text] [PDF]